ITGAL can promote an increase in the ratio of CD4 and CD8 T cells, improving the survival rate of patients with metastatic melanoma, which may explain why high expression of ITGAL is associated with a better prognosis. The gene discussed is CD8A; the disease is metastatic melanoma.